PortfoliosLab logoPortfoliosLab logo
SMMT vs. AXON
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SMMT vs. AXON - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Summit Therapeutics Inc. (SMMT) and Axon Enterprise, Inc. (AXON). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SMMT achieves a -19.90% return, which is significantly higher than AXON's -22.22% return. Over the past 10 years, SMMT has underperformed AXON with an annualized return of 5.31%, while AXON has yielded a comparatively higher 34.58% annualized return.


SMMT

1D
7.11%
1M
-25.44%
YTD
-19.90%
6M
-20.26%
1Y
-30.51%
3Y*
93.96%
5Y*
15.49%
10Y*
5.31%

AXON

1D
-1.00%
1M
17.23%
YTD
-22.22%
6M
-21.72%
1Y
-43.02%
3Y*
30.96%
5Y*
22.92%
10Y*
34.58%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SMMT vs. AXON - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SMMT
Summit Therapeutics Inc.
-19.90%-1.99%583.72%-38.59%57.99%-42.77%193.75%39.13%-89.62%29.44%
AXON
Axon Enterprise, Inc.
-22.22%-4.44%130.06%55.69%5.69%28.13%67.21%67.50%65.09%9.32%

Correlation

The correlation between SMMT and AXON is 0.02, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.02

Correlation (3Y)
Calculated over the trailing 3-year period

0.09

Correlation (5Y)
Calculated over the trailing 5-year period

0.11

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Mar 5, 2015

0.10

Fundamentals

Market Cap

SMMT:

$10.86B

AXON:

$36.43B

EPS

SMMT:

-$1.60

AXON:

$2.41

PB Ratio

SMMT:

19.90

AXON:

10.31

Total Revenue (TTM)

SMMT:

$0.00

AXON:

$2.98B

Gross Profit (TTM)

SMMT:

-$83.36K

AXON:

$1.77B

EBITDA (TTM)

SMMT:

-$738.34M

AXON:

$156.24M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SMMT vs. AXON — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SMMT
SMMT Risk / Return Rank: 2626
Overall Rank
SMMT Sharpe Ratio Rank: 2525
Sharpe Ratio Rank
SMMT Sortino Ratio Rank: 2929
Sortino Ratio Rank
SMMT Omega Ratio Rank: 2929
Omega Ratio Rank
SMMT Calmar Ratio Rank: 2323
Calmar Ratio Rank
SMMT Martin Ratio Rank: 2626
Martin Ratio Rank

AXON
AXON Risk / Return Rank: 1313
Overall Rank
AXON Sharpe Ratio Rank: 1111
Sharpe Ratio Rank
AXON Sortino Ratio Rank: 1212
Sortino Ratio Rank
AXON Omega Ratio Rank: 1212
Omega Ratio Rank
AXON Calmar Ratio Rank: 1616
Calmar Ratio Rank
AXON Martin Ratio Rank: 1515
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SMMT vs. AXON - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Summit Therapeutics Inc. (SMMT) and Axon Enterprise, Inc. (AXON). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


SMMTAXONDifference
Sharpe ratioReturn per unit of total volatility

+0.37

Sortino ratioReturn per unit of downside risk

+0.91

Omega ratioGain probability vs. loss probability

0.98

0.87

+0.11

Calmar ratioReturn relative to maximum drawdown

-0.55

-0.72

+0.16

Martin ratioReturn relative to average drawdown

-0.87

-1.22

+0.34

SMMT vs. AXON - Sharpe Ratio Comparison

The current SMMT Sharpe Ratio is -0.41, which is higher than the AXON Sharpe Ratio of -0.78. The chart below compares the historical Sharpe Ratios of SMMT and AXON, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

SMMT vs. AXON - Drawdown Comparison

The maximum SMMT drawdown since its inception was -95.75%, roughly equal to the maximum AXON drawdown of -91.78%. Use the drawdown chart below to compare losses from any high point for SMMT and AXON.


Loading charts...

Drawdown Indicators


SMMTAXONDifference

Max Drawdown

Largest peak-to-trough decline

-95.75%

-91.78%

-3.97%

Max Drawdown (1Y)

Largest decline over 1 year

-55.49%

-60.28%

+4.79%

Max Drawdown (3Y)

Largest decline over 3 years

-64.44%

-60.28%

-4.16%

Max Drawdown (5Y)

Largest decline over 5 years

-91.78%

-60.28%

-31.50%

Max Drawdown (10Y)

Largest decline over 10 years

-95.75%

-60.28%

-35.47%

Current Drawdown

Current decline from peak

-61.83%

-49.28%

-12.55%

Average Drawdown

Average peak-to-trough decline

-57.63%

-43.60%

-14.03%

Ulcer Index

Depth and duration of drawdowns from previous peaks

34.94%

35.34%

-0.40%

Volatility

SMMT vs. AXON - Volatility Comparison

Summit Therapeutics Inc. (SMMT) has a higher volatility of 23.99% compared to Axon Enterprise, Inc. (AXON) at 17.73%. This indicates that SMMT's price experiences larger fluctuations and is considered to be riskier than AXON based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SMMTAXONDifference

Volatility (1M)

Calculated over the trailing 1-month period

23.99%

17.73%

+6.26%

Volatility (6M)

Calculated over the trailing 6-month period

56.65%

44.20%

+12.45%

Volatility (1Y)

Calculated over the trailing 1-year period

75.61%

55.66%

+19.95%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

185.08%

47.94%

+137.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

144.46%

49.18%

+95.28%

Dividends

SMMT vs. AXON - Dividend Comparison

Neither SMMT nor AXON has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

SMMT vs. AXON - Financials Comparison

This section allows you to compare key financial metrics between Summit Therapeutics Inc. and Axon Enterprise, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M202220232024202520260
807.35M
(SMMT) Total Revenue
(AXON) Total Revenue
Values in USD except per share items

Frequently Asked Questions


SMMT and AXON have a correlation of 0.02, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SMMT has higher volatility (23.99%) compared to AXON (17.73%). In terms of maximum drawdown, SMMT dropped -95.75% vs AXON's -91.78%.

SMMT currently has the higher Sharpe Ratio (-0.41 vs -0.78), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SMMT and AXON

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer